Roivant Sciences Ltd (NASDAQ:ROIV) Expected to Post Quarterly Sales of $10.13 Million

Analysts expect Roivant Sciences Ltd (NASDAQ:ROIV) to announce sales of $10.13 million for the current quarter, according to Zacks. Two analysts have provided estimates for Roivant Sciences’ earnings, with estimates ranging from $6.00 million to $14.27 million. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Roivant Sciences will report full-year sales of $36.99 million for the current fiscal year, with estimates ranging from $31.70 million to $50.54 million. For the next financial year, analysts anticipate that the company will report sales of $44.88 million, with estimates ranging from $8.40 million to $92.11 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Roivant Sciences.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, November 15th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.19. The company had revenue of $13.99 million for the quarter, compared to the consensus estimate of $5.30 million.

ROIV has been the subject of several research analyst reports. Citigroup initiated coverage on Roivant Sciences in a research report on Wednesday, October 27th. They issued a “buy” rating and a $11.00 price objective for the company. Truist initiated coverage on Roivant Sciences in a research report on Tuesday, October 26th. They issued a “buy” rating and a $15.00 price objective for the company. Jefferies Financial Group initiated coverage on Roivant Sciences in a research report on Tuesday, October 26th. They issued a “buy” rating and a $10.00 price objective for the company. HC Wainwright began coverage on Roivant Sciences in a research report on Monday, November 8th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Truist Securities began coverage on Roivant Sciences in a research note on Tuesday, October 26th. They issued a “buy” rating and a $15.00 target price for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Roivant Sciences has an average rating of “Buy” and a consensus price target of $13.00.

Shares of ROIV opened at $7.95 on Friday. The company has a fifty day simple moving average of $9.93. Roivant Sciences has a 52-week low of $5.80 and a 52-week high of $16.76.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

Featured Article: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Roivant Sciences (ROIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.